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Although many cancer patients use complementary and alternative medicine, including Agaricus blazei Murill (ABM), safety is
notyet well understood. Cancer survivors took 1.8,3.6,or 5.4g ABM granulated powder (KyowaWellness Co., Ltd., Tokyo, Japan)
per day orally for 6 months. Adverse events were deﬁned by subjective/objective symptoms and laboratory data according to
the National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0 (NCI-CTCAE v3.0). Seventy-eight
patients were assessed for safety of ABM (30/24/24 subjects at 1/2/3 packs per day, resp.). Adverse events were observed in 9
patients (12%). Most were digestive in nature such as nausea and diarrhea, and one patient developed a liver dysfunction-related
food allergy, drug lymphocyte product. However, none of these adverse events occurred in a dose-dependent manner. This study
showsthat ABM does not cause problems in most patients within laboratory parameters at the dosages tested over 6 months.This
trial supports previous evidence that the ABM product is generally safe, excluding possible allergic reaction.
1.Introduction
The prevalence of complementary and alternative medicine
(CAM) is increasing worldwide due to growing public
interest in natural or holistic therapies and the ﬂow of
information via the Internet and mass media. In Japan,
the research division supported by a Grant-in-Aid Cancer
Research from the Ministry of Health, Labor and Welfare has
performed a nationwide cross-sectional survey to evaluate
the prevalence of CAM use in cancer patients and their
perceptions of cancer CAM, and especially of CAM products
used [1]. The survey found a prevalence of CAM use of
44.6% (1382 of 3100) in Japanese cancer patients. The
most frequently used CAM products were mushrooms
(Agaricus 60.6%, active hexose-correlated compound 8.4%,
and Ganoderma lucidum 6.3%).
Agaricus products are extracted from the Agaricus blazei
Murill mushroom. Agaricus blazei Murill (popularly known
as “Cogumelo do Sol”i nB r a z i la n d“ Himematsutake”i n
Japan) is a mushroom native to Brazil and widely culti-
vated in Japan for medicinal use. In Brazil, Agaricus is
traditionally used against a variety of diseases such as dia-
betes, atherosclerosis, hepatitis, hypercholesterolemia, and
heart disease [2]. In Japan, researchers have demonstrated
antioxidant, antimutagenic, antitumor, cancer inhibitory,
cancer preventive and immunoenhancing eﬀects of Agaricus
blazei Murill experimentally [3–12]. Experimental studies
haveespeciallypopularizedAgaricus blazeiMurillmushroom
use in Japan, resulting in increased commercial interest
stimulating not only production but also registration of new
brands and products. No signiﬁcant toxicity was shown in
either the subchronic (SPF-derived F344 rats and beagle
dogs) or the two-year chronic bioassay study in experimental
animals (SPF-derivedF344 rats) (1998∼2002)in compliance
to the FDA GLP Guideline [13].
Since 1991, Agaricus blazei Murill has become a very
popular dietary supplement in Japan. For the ﬁrst 10 years,
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hundreds of thousands with no reports of any serious side
eﬀects associated with Agaricus blazei Murill consumption.
But in 2001, a clinical case was reported of 3 terminal cancer
patients [IIIC ovarian cancer, IIIA, breast cancer, and a
metastatic breast cancer (HBVcarrier)], who had undergone
a regimen of multiple combination chemotherapy and
Agaricus blazei Murill supplement consumption. All 3 were
shown to have severe acute hepatitis with a fatal outcome
for 2 and there ensued speculation that the hepatitis could
be attributed to Agaricus blazei Murill intake [14]. However,
throughout the long history of cancer chemotherapy, it
has been amply documented (over 1,000 publications) that
either a single or a combination chemotherapy either with-
outorwithradiationtreatmentcanfrequentlycauseanacute
to fatal hepatitis or sudden death due to a lethal potentiation
of chemotherapeutic agents by microquantity of endotoxin
in cancer patients [15–25]. Furthermore, treatment using
radiation or chemotherapeutic agent(s) has been shown to
causeafatalreactivationofchronichepatitisBvirusinfection
in cancer patients who are chronic hepatitis carriers [26–
28]. In contrast, a clinical placebo-controlled toxicity study
demonstrated no signiﬁcant toxicological ﬁndings [29, 30].
Numerous other clinical studies with Agaricus blazei Murill
showed no signiﬁcant toxicities including acute hepatitis
or severe hepatotoxicity [31–41]. Nonetheless, this clinical
case report prompted the Japanese Food Safety Committee
appointed by Japanese Government to evaluate the safety
of Agaricus blazei Murill dietary supplement products. In
a preliminary genetic toxicity study result, only one of
3 commercial Agaricus blazei Murill products tested was
reported to be positive. This preliminary Ames’ test result
was made public on February 13, 2006 by the Ministry
of Health, Labor, and Welfare [42]. Immediately after this
announcement, the Agaricus blazei Murill dietary supple-
ment product shown to be Ames’ positive was voluntarily
withdrawn from the market with no further production,
while all other Agaricus blazei Murill dietary supplement
producers continued to market their Agaricus blazei Murill
products. In August, 2006, the Agaricus blazei Murill mush-
room industry in Japan organized the Agaricus Product
Association to establish the guidelines to evaluate the safety,
eﬃcacy, quality control and monitoring of all publications
relevant to Agaricus dietary supplements [43]. The initial
Ames’ test results were further scrutinized carefully and
more thoroughly by using the transgenic F344 rat LacI,
a state-of-the-art genetic toxicity testing system [44]. The
outcome demonstrated irrefutable negative results with the
identical sample [45], which had been initially announced
to be positive and withdrawn from the market. Clearly the
initial Ames’ test was improperly executed resulting in a
false positive [46–49] and too hastily announced by oﬃcials
without further validation of the preliminary Ames’ test
results.
There are at least 20 manufacturers and approximately
100 Agaricus mushroom-derived dietary supplements. The
annual consumption of these dietary supplements derived
from Agaricus blazei Murill mushroom is approximately 15∼
20 tons in Japan. Owing to these signiﬁcant numbers, the
Japanese Ministry of Health, Labor, and Welfare has become
interested in the safety of commercial Agaricus mushroom
supplements among Japanese consumers and therefore
supported the objective of this clinical study to evaluate
Agaricus blazei Murill safety. The rationale for selecting
which Agaricus dietary supplements to be tested was based
on the annual consumption of each commercial Agaricus
dietary supplement. Annually, 70% of Japanese consumers
chose Kyowa’s Sen-Sei-Ro products (Kyowa Wellness, Co,
Ltd., Tokyo, Japan) over those of any other commercial
Agaricus products. Unfortunately, due to limited funding for
this clinical trial, the study scale had to be restricted to 80
patients.
The study product was purchased by public research
fund Grant-in-Aid for Cancer Research from the Ministry of
Health, Labor andWelfare, Japan. Noresearcher in this study
had any ﬁnancial or other conﬂict of interests.
2.Subjectsand Methods
This study was approved by the institutional review board
of the Kanazawa University Hospital and Shikoku Cancer
Center. Patients were recruited by the Department of
Obstetrics and Gynecology of Kanazawa University Hospital
and the Department of Urology of Shikoku Cancer Center,
respectively. Prior to enrollment, all patients were provided
and required to sign written informed consent. Data man-
agementwithrespecttoadverseeﬀectsofthetestsupplement
was performed independently by the Monitoring and Evalu-
ation Committee for Clinical Eﬃcacy and Adverse Eﬀects.
2.1. Criteria for the Eligibility. Eligibilitycriteria (Table 1)f or
inclusion were cancer patients, who were in complete remis-
sion with no clinical evidence of relapse of cancer based on
(i) a routine follow-up clinical evaluation following radical
surgery, radiation, and chemotherapy, (ii) no cancer therapy
within 30 days of onset of the study, (iii) no use of dietary
supplements, and (iv) no evidence of severe organ dysfunc-
tion (aspartate aminotransferase, alanine aminotransferase,
alkaline phosphatase, and r-glutamyl transpeptidase levels
withintwicetheupperlimitsofnormalranges).Patientswho
met eligibility criteria for the study were recruited between
February and August of 2008.
Demographic and clinical characteristics of the enrolled
patients (n = 78, 46 male, 32 female) previously treated are
shown in Table 1. The mean age of 78 patients was 65.6 ±
10.3 (ages ranged 29∼79 years old). Of these 78 patients
cancerdiagnosesrangedfromprostate,endometrial,bladder,
ovarian, cervical,gastric, toothers thatincludedendometrial
stromal sarcoma, uterine sarcoma, vaginal cancer, oral
leukoplakia, breast cancer, and renal cell carcinoma of early
and advanced stages. Treatment received prior to enrollment
included surgery (57 patients), chemotherapy (19 patients),
and radiotherapy (30 patients), respectively.
2.2. Study Protocols. The chosen test product, “Sen-Sei-
Ro Powder Gold, contains 1800mg lyophilized, granulated
powder per pack. One pack contains the following: car-
bohydrates 820mg, protein 488mg, food grade celluloseEvidence-Based Complementary and Alternative Medicine 3
Table 1: Inclusion criteria for eligibility and demographic and
clinical characteristics of patients previously treated (n = 78).
Radical operation for cancer and completely
recovered from operation
No cancer therapy within 30 days
No use of supplements
No severe organ dysfunction
Age 20–80
Written informed consent
Number of patients 78
Age (year)
Mean ± standard deviation 65.6 ± 10.3
Range 29−79
Gender (Male/Female) 46/32
Diagnosis Number of
patients
Prostate cancer (early/advance) 38 (38/0)
Endometrial cancer (early/advance) 12 (8/4)
Bladder cancer (early/advance) 8 (6/2)
Ovarian cancer (early/advance) 6 (3/3)
Cervical cancer (early/advance) 6 (3/3)
Gastric cancer (early/advance) 2 (2/0)
Others (number of patients) (early/advance) 6 (2/4)
Endometrial stromal sarcoma (1), uterine
sarcoma (1), vaginal cancer (1), oral cavity
cancer (1),
Breast cancer (1), renal cell carcinoma (1)
Previous treatment Number of
patients
Operation 57
Chemotherapy 19
Radiotherapy 30
Blood test Blood test Blood test Blood test
02 4 6
2months 2months 2months
Subjects enrolled and
informed written
consent obtained
Figure 1: Study schedule.
(dietary ﬁber) 284mg, fat 47mg, and sodium 0.19mg.
According to the 2009 Physician’s Desk Reference, water (at
68mg/pack) contains the following: 0.1mgFe, 0.24mgCa,
37mgK, 0.01mg thiamine, 0.04mg ergosterol, and 0.59mg
niacin. Results from tests for heavy metals (mercury, cad-
mium, lead, and arsenic) conformed to strict Japanese food
regulations. Safety evaluation was based on laboratory data
Table 2: The deﬁnition of a causal relationship between the study
and the adverse event.
Variable Deﬁnition
Unrelated
The event is clearly not related to the
investigational agent
∗A causal relationship is biologically implausible
Possible
The event may be related to the investigational
agent
∗An alternative explanation for the adverse event
is present
For example concurrent administered
medication, invasive surgical procedure
Probable
The event is likely to be related to the
investigational agent
∗A temporal relationship between the study and
the onset of the adverse event is present
For example recurrence of symptom by
readministration
∗An alternative explanation for the adverse event
is not present
Deﬁnite
The event is clearly related to the investigational
agent
∗A causal relationship is biologically explicable
and subjective/objective symptoms obtained at baseline and
after 2, 4, and 6 months of exposure to the test product.
The ﬁrst 30 subjects were assigned to the lowest dose
group (1pack/day), the next 24 subjects were assigned to the
mid-dose group (2packs/day), and the last 24 subjects were
assigned to the highest dose group (3packs/day). Subjects
diurnally took 1 (1.8g), 2 (3.6g), or 3 (5.4g) packs/day
orally for 6 months. The following laboratory parameters
were measured: white blood cell (WBC) count, red blood
cell (RBC) count, hemoglobin (Hb), hematocrit (Ht),
platelet count, aspartate aminotransferase (AST), alanine
aminotransferase (ALT),gamma glutamyltranspeptidase (γ-
GTP), alkaline phosphatase (ALP), total bilirubin (T-bil),
total cholesterol (T-cho), total protein (TP), albumin, blood
urea nitrogen (BUN), creatinine, sodium (Na), potassium
(K), chlorine (Cl), and C-reactive protein (CRP). The
intervention schedule is shown in Figure 1.
Statistical Analysis. ANOVA analysis was used to identify
signiﬁcant diﬀerencesinthebloodchemistry beforeandafter
1, 2, and 3 packs of Sen-Sei-Ro intake.
2.3. Adverse Event Deﬁnitions and Causality. Adverse events
were deﬁned by subjective/objective symptoms and labora-
tory data in accordance with the National Cancer Institute
Common Terminology Criteria for Adverse Events version
3.0 (NCI-CTCAE v3.0). An adverse event was deﬁned as
any undesirable event that occurred to a patient during the
course of the study. The deﬁnition of a causal relationship
between study and adverse event is shown in Table 2.4 Evidence-Based Complementary and Alternative Medicine
Table 3: Summary of the major adverse events.
Patient no. Sex Tumor type Symptoms Concurrently
administered medication
Causality Safety trial
One pack/day
Patient no. 6 Male Bladder cancer Lower abdominaldiscomfort (G1) Betaxolol hydrochloride,
nitrendipine
Possible Complete
Patient no. 11 Male Prostate cancer
Hand tremor and dizziness when
given concomitantlywith cold
medication (G1)
Cold medication Possible Incomplete
Patient no. 19 Male Prostate cancer Nausea (G1)
Glimepiride,
allopurinol,
mecobalamin
Probable Incomplete
Patient no. 55 Female Ovarian cancer Elevated AST (G1) and total
bilirubin (G1), urticaria (G3) — Deﬁnite Incomplete
Two packs/day
Patient no. 27 Male Prostate cancer Diarrhea (G1) Allopurinol, losartan
potassium
Possible Complete
Patient no. 32 Male Prostate cancer Occurrence of other cancer (G4) Unrelated Incomplete
Patient no. 34 Male Prostate cancer Nausea (G1)
Nicardipine,
trichlormethiazide,
carteolol
Possible Incomplete
Three packs/day
Patient no. 4 Female Cervical cancer Obstruction, gastrointestinal (G2) — Possible Incomplete
Patient no. 38 Male Prostate cancer Lower abdominaldiscomfort (G1) — Probable Incomplete
3.Results
3.1. Patients. Eighty-one patients met eligibility criteria
and enrolled for the study. Of the 81 enrollees, 78 were
assessed for safety evaluation of Agaricus blazei Murill while
three patients withdrew consent for intervention. The three
patients who withdrew may have been unable to tolerate the
preparation ofthe ﬁnely granulated powder not the Agaricus
itself.Therewerenosubjectswhocouldnottoleratethesmell
and taste of the product. Characteristics of the 78 patients
surveyed are shown in Table 1.C o m p l i a n c ew a sg r e a t e rt h a n
90% in all patients.
3.2.Subjective/Objective Symptoms. A summary ofthemajor
adverse events in nine patients (12%) is shown in Table 3.
SevenofninepatientsdiscontinuedconsumptionofAgaricus
blazei Murill granulated powder before the safety trial was
completed. In addition, one patient stopped taking the
supplement ﬁve months after the start of the trial due to
diagnosis of a primary tumor recurrence.
In Table 3,p a t i e n tn o .5 5( 5 9 - y e a r - o l df e m a l e ,o v a r i a n
cancer) was enrolled in the study after cancer-related surgery
and six cycles of chemotherapy (Paclitaxel/Carboplatin) as a
postoperative adjuvant therapy. Two months after beginning
consumption of Agaricus, she complained of generalized
urticaria. When she visited the hospital, liver dysfunction
(AST 24 (reference value 13–33), ALT 31(ref. 6–27), T-bil
1.7 (ref. 0.3–1.2)), and urticarial papulae were observed.
Agaricus consumption was immediately discontinued and
she was injected with a hepatoprotector and given oral
antiallergy drugs. Three weeks later laboratory data were
within normal limits and urticarial papulaehad disappeared.
A drug lymphocyte stimulation test (DLST) against Agaricus
blazei Murill product was positive. She had no particular
past history of allergic reactions. The causal relationship
between Agaricus blazei Murill and these adverse events was
considered “Deﬁnite.”
Patient no. 19 (69-year-old male, prostate cancer) was
enrolledin thestudyaftercancer-relatedsurgery. Onemonth
after beginning consumption of Agaricus, he felt nausea.
This stopped when he discontinued the supplement but
started again when he restarted Agaricus. The causal rela-
tionship between Agaricus and this nausea was considered
“Probable.”
Patient no. 4 (47-year-old female) was enrolled in the
study one month after a radical hysterectomy for uterine
cervical cancer. One month after beginning consumption
of Agaricus, she complained of abdominal pain. She dis-
continued the supplement when diagnostic imaging showed
an intestinal obstruction. A week after discontinuation,
the obstruction had disappeared. Although she did not
restart the supplement, one month later the obstruction
reoccurred. The causal relationship between Agaricus and
this obstruction was considered “Possible.”
Although transitory digestive symptoms were observed
in patients no. 6 (70-year-old male, bladder cancer) and no.
27 (70-years-old male, prostate cancer), they continued in
the trial without any treatment foradverse events.The causal
relationship between Agaricus and this digestive discomfort
was considered “Possible.” Causality of adverse events in
otherpatients(no.11,no.32,no.34,andno.38)wasdecided
according to the deﬁnition shown in Table 2.Evidence-Based Complementary and Alternative Medicine 5
Table 4: Adverse events of blood biochemical ﬁndings (n = 78).
Event Daily intake Grade 1 (%) ≥Grade 2 (%)
Blood/bone marrow
1p a c k( n = 30) 1 (3) 0 (0)
White blood cell 2 packs (n = 24) 0 (0) 0 (0)
3p a c k s( n = 24) 0 (0) 0 (0)
1p a c k( n = 30) 2 (7) 0 (0)
Hemoglobin 2 packs (n = 24) 2 (8) 0 (0)
3p a c k s( n = 24) 1 (4) 0 (0)
1p a c k( n = 30) 0 (0) 0 (0)
Platelets 2 packs (n = 24) 0 (0) 0 (0)
3p a c k s( n = 24) 0 (0) 0 (0)
Metabolic/laboratory
1p a c k( n = 30) 0 (0) 0 (0)
Aspartate aminotransferase(AST) 2 packs (n = 24) 1 (4) 0 (0)
3p a c k s( n = 24) 2 (8) 0 (0)
1p a c k( n = 30) 2 (7) 0 (0)
Alanine aminotransferase(ALT) 2 packs (n = 24) 0 (0) 0 (0)
3p a c k s( n = 24) 0 (0) 0 (0)
1p a c k( n = 30) 0 (0) 0 (0)
g-glutamyl transpeptidase (GTP) 2 packs (n = 24) 1 (4) 0 (0)
3p a c k s( n = 24) 0 (0) 0 (0)
1p a c k( n = 30) 1 (3) 0 (0)
Alkaline phosphatase 2 packs (n = 24) 0 (0) 0 (0)
3p a c k s( n = 24) 1 (4) 0 (0)
1p a c k( n = 30) 3 (10) 0 (0)
Total bilirubin 2 packs (n = 24) 0 (0) 0 (0)
3p a c k s( n = 24) 0 (0) 0 (0)
1p a c k( n = 30) 0 (0) 0 (0)
Total cholesterol 2 packs (n = 24) 1 (4) 0 (0)
3p a c k s( n = 24) 0 (0) 0 (0)
1p a c k( n = 30) 2 (7) 0 (0)
Albumin 2 packs (n = 24) 0 (0) 0 (0)
3p a c k s( n = 24) 0 (0) 0 (0)
1p a c k( n = 30) 0 (0) 0 (0)
Creatinine 2 packs (n = 24) 0 (0) 0 (0)
3p a c k s( n = 24) 1 (4) 0 (0)
1p a c k( n = 30) 1 (3) 0 (0)
Na, high 2 packs (n = 24) 0 (0) 0 (0)
3p a c k s( n = 24) 0 (0) 0 (0)
1p a c k( n = 30) 2 (7) 0 (0)
K, high 2 packs (n = 24) 0 (0) 0 (0)
3p a c k s( n = 24) 1 (4) 0 (0)
1p a c k( n = 30) 1 (4) 0 (0)
K, low 2 packs (n = 24) 0 (0) 0 (0)
3p a c k s( n = 24) 0 (0) 0 (0)
3.3. Laboratory Data. Adverse events from blood biochemi-
cal ﬁndings are shown in Table 4. When patients with abnor-
mal levels continued taking the supplement, all laboratory
datareturned to normal limits withoutany treatment during
the course of study (with the exception of patient no. 55,
Table 3). Assessed clinical test items other than those of
Table 4 had no apparent abnormalities. No blood chemistry
values were signiﬁcantly diﬀerent from the pretreatment
values with the exception of RBC (P = .04), hemoglobin
(P = .03), hematocrit (P = .005), total cholesterol (P = .02),6 Evidence-Based Complementary and Alternative Medicine
Clinical study
 Improvement of quality of life and
natural killer cell activity
in gynecological cancer patients
 Improvement of hypertension
 Improvement of hypercholesterolemia and obesity
 Improvement of hepatitis C
Mycelium Unidentiﬁed
substance
Food allergy
Digestive discomfort
Liver dysfunction
Not substantiated
Contact dermatitis
Clinical study
Fruiting
body Pyroglutamate
Ergosterol
Antiangiogenic
Lignin derivatives
Polysaccharide
β-glucan
Immunomodulation
Macrophage activation
N a t u r a lk i l l e rc e l la c t i v a t i o n
Dendritic cell stimulation
Complement activation
T-helper-1(Th1) response ⇑
Interferon-γ production ⇑
In vitro and animal
Positive eﬀect Potential negative eﬀect
In vitro and animal
Agaritine
Heavy metal
Not carcinogenic
No toxicity has been
reported
e.g. arsenic, lead,
cadmium, mercury
Figure 2: The opposite reaction of Agaricus blazei Murill derivatives. Our study of safety clinical trail showed that food allergy and digestive
discomfort, associated with Agaricus blazei Murill product, were noted as new ﬁndings.
TP (P = .02), and creatinine (P = .04). However, these
diﬀerences were mild, transient, and quickly returned to
normal (laboratory blood chemistry data not shown).
4.Discussion
Despitethenumerousreportsregarding thepreclinicalsafety
and eﬃcacy of Agaricus blazei derivatives, further evaluation
is needed.
Itisnoteworthy thatincidenceofacutehepatitisismostly
limited to a single or very few clinical case report(s) among
cancer patients, who have undergone chemotherapy with
episodic consumption of Agaricus blazei Murill, while no
such severe acute hepatitis or fatal liver failure was observed
in many placebo-controlled clinical studies involving Agari-
cus blazei Murill intake [42–53].
Foodallergyanddigestivediscomforthavebeenrecorded
as new ﬁndings (Figure 2).Additionalclinicalsafety trials are
necessary.
Among the 78 subjects, one (1/78 or 1%) food allergy
caused by Agaricus blazei Murill was observed. Agaricus
has been reported to possess biological eﬀects including
immunomodulatory and tumoricidal activities, which are
due to induction of Th1 response, not the Th2 response
induced by IgE-mediated allergies. Moreover, Ellertsen et
al. have shown that Agaricus may both prevent allergy
development and therapeutically treat established allergies
[50]. However, a food allergy to Agaricus is a possible
eventuality in all people, including cancer survivors.
Mushrooms are antigenically rich, but the overall extent
of mushroom allergies is unknown [51]. The genus Agaricus
has been reported as a contact sensitizer in the past [52–
55]. Recently, exudative erythema multiforme [56]a n d
chronic cheilitis [57]f r o mAgaricus blazei Murill have been
reported. Moreover, Herrera-Mozo et al. demonstrated the
existence of a new allergen responsible for cross-reactivity
betweenAgaricusbisporusandspinach andmolds(Alternaria
alternata, Cladosporium herbarum,a n d / o rAspergillus fumi-
gatus) in allergic patients [58]. At present, the cross-reacting
antigen between Agaricus blazei Murill and the other foods
or allergens has not been identiﬁed. The patient (no. 55)
who complained of urticaria in this study had nothing par-
ticularly noteworthy in her past medical history, including
allergic reactions.
The present study found that digestive symptoms such
as nausea and diarrhea were observed infrequently. In
contrast, patients with constipation reported improvement
of digestive function, probably as a result of the high
dietary ﬁber (284mg/pack) contained in Agaricus blazei
Murill granulated powder. Gastrointestinal manifestations
associated with Agaricus may be inﬂuenced by patient
condition and responsiveness.
It is also important to consider natural variability of
Agaricus. Agaricus blazei Murill dietary supplements are nat-
ural products whose chemical compositions vary, depending
on factors such as geographic source, climate, and time
of harvest of mushroom. Commercially available products
also vary from manufacturer to manufacturer in contentEvidence-Based Complementary and Alternative Medicine 7
and concentration of chemical constituents, and even from
batch to batch within the same product. Even when natural
products are standardized for content of known active or
marker compounds to achieve a more consistent phar-
maceutical quality, there is nevertheless variation in the
concentration of other constituents, which may modulate
or potentiate the eﬀectiveness of the active ingredient.
These variations can result in diﬀerences in pharmacologic
activity in vitro as well as in bioavailability to humans.
Dealing with consistency issues is critical, and in Japan
industry groups have recently begun imposing voluntary
standards of product safety. Nevertheless, the government
may also need to set rules for testing the safety of dietary
supplements.
With regard to safety issues related to consumption
of Agaricus mushroom as food or dietary supplements, it
contains a wide range of naturally occurring agaritine and
heavy metal such as cadmium. The Japanese Food Safety
Committee commissioned by the Japanese government was
concerned with the potential carcinogenicity of agaritine
present in both Agaricus blazei and Agaricus bisporus despite
the existence of several publications of negative results of
2-year chronic carcinogenicity studies with both Agaricus
blazei Murill [13] Agaricus bisporus [59]a n dt h eh i g hd o s eo f
agaritine[60,61].Arecentvalidationstudyofagaritine using
Stratagene’s F344 lacI rats failed to demonstrate the presence
of DNA adducts of agarithine’s potent mutagenic metabo-
lite(s) following daily intake of 80mgagaritine/kg/daily/90
days [45]. Kyowa’s Powder Gold contains 5ppm of cadmium
or less per pack. Hence a regimen of three packs per day
equates to a daily cadmium intake of 15ppm or less. This
level of cadmium intake is only 25% of permissible levels in
food [62].
In conclusion, the present preliminary clinical study (78
subjects) shows that Agaricus blazei Murill granulated pow-
der is well tolerated in most patients and that supplement
doses of 1.8/3.6/5.4g per day for 6 months did not cause
abnormalities within laboratoryparameters. This small-scale
clinicaltrialappearstosupporttheevidencethattheAgaricus
blazei Murill product manufactured by Kyowa Wellness is
safe except for the infrequent occurrence of allergic reaction.
The present clinical study results provide an important
data basis for a larger-scale clinical study with standardized
Agaricus product to further validate and support the current
ﬁndings.
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